LIXTLIXTE BIOTECHNOLOGY HOLDING...

Nasdaq lixte.com


$ 3.30 $ 0.04 (1.24 %)    

Tuesday, 23-Apr-2024 15:22:26 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 3.26
$ 3.35
$ 0.00 x 0
$ 3.26 x 100
$ 3.30 - $ 3.46
$ 1.58 - $ 9.50
4,162
na
6.25M
$ 0.68
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-19-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-09-2023 06-30-2023 10-Q
4 05-10-2023 03-31-2023 10-Q
5 03-29-2023 12-31-2022 10-K
6 11-08-2022 09-30-2022 10-Q
7 08-10-2022 06-30-2022 10-Q
8 05-11-2022 03-31-2022 10-Q
9 03-21-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-10-2021 06-30-2021 10-Q
12 05-12-2021 03-31-2021 10-Q
13 03-26-2021 12-31-2020 10-K
14 11-10-2020 09-30-2020 10-Q
15 08-10-2020 06-30-2020 10-Q
16 05-11-2020 03-31-2020 10-Q
17 03-25-2020 12-31-2019 10-K
18 11-08-2019 09-30-2019 10-Q
19 08-06-2019 06-30-2019 10-Q
20 05-09-2019 03-31-2019 10-Q
21 03-25-2019 12-31-2018 10-K
22 11-08-2018 09-30-2018 10-Q
23 08-02-2018 06-30-2018 10-Q
24 04-27-2018 03-31-2018 10-Q
25 03-23-2018 12-31-2017 10-K
26 11-09-2017 09-30-2017 10-Q
27 08-04-2017 06-30-2017 10-Q
28 05-10-2017 03-31-2017 10-Q
29 03-29-2017 12-31-2016 10-K
30 11-04-2016 09-30-2016 10-Q
31 08-10-2016 06-30-2016 10-Q
32 05-06-2016 03-31-2016 10-Q
33 03-28-2016 12-31-2015 10-K
34 11-10-2015 09-30-2015 10-Q
35 08-07-2015 06-30-2015 10-Q
36 05-13-2015 03-31-2015 10-Q
37 03-27-2015 12-31-2014 10-K
38 11-12-2014 09-30-2014 10-Q
39 08-08-2014 06-30-2014 10-Q
40 05-09-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 lixte-biotechnology-holdings-files-50m-offering

-SEC Filing

 watching-lixte-biotechnology-white-diamond-research-posts-on-x-breaking-news-lixte-biotechnology-lied-its-publication-yesterday-isnt-new--its-the-same-one-they-published-over-a-year-ago

White Diamond on X: "BREAKING NEWS: Lixte Biotechnology Lied: Its Publication Yesterday Isn't New – It's The Same O...

 gold-moves-higher-velo3d-shares-plummet

U.S. stocks traded mostly higher toward the end of trading, with the Dow Jones index gaining over 300 points on Wednesday. The...

 why-luxurban-hotels-shares-are-trading-lower-by-around-27-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of LuxUrban Hotels Inc. (NASDAQ: LUXH) fell sharply during Wednesday’s session after the company issued preliminary fo...

 crude-oil-edges-lower-paysign-shares-spike-higher

U.S. stocks traded mostly higher midway through trading, with the Dow Jones gaining over 200 points on Wednesday. The Dow trad...

 why-lixte-biotechnology-stock-is-soaring

The company announced the publication of pre-clinical data in the online journal, "Cancer Discovery", showing that its ...

 dow-jumps-over-200-points-unifirst-posts-downbeat-earnings

U.S. stocks traded higher this morning, with the Dow Jones gaining over 200 points on Wednesday. Following the market opening ...

 lixte-biotechnology-holdings-publication-pre-clinical-data-in-cancer-discovery-regarding-lb-100

LB-100 IS SYNERGISTIC WITH WEE1 INHIBITION IN KILLING CANCER CELLS; FINDING OPENS NEW TREATMENT STRATEGY IN ADDITION TO THREE C...

 lixte-provides-update-on-progress-with-lb-100-as-a-pp2a-inhibitor-to-enhance-chemotherapy-and-immunotherapy-cancer-treatments

-- Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers --PASADENA, Calif., March 21, 2024 (...

 lixte-biotechnology-announces-presentation-of-pre-clinical-data-on-lixtes-lb-100-at-joint-conference-of-european-and-american-associations-for-cancer-research

Conference In Dublin, Ireland on February 27 - 29, 2024Focuses on How to Bring Basic Science Discoveries to the Clinic

 lixte-biotechnology-granted-us-patent--11866444-oxabicycloheptane-prodrugs

https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11866444

 lixte-biotechnology-provides-update-on-clinical-progress-and-expanding-collaborations

LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical co...

 lixte-netherlands-cancer-institute-and-oncode-institute-to-expand-collaboration

Extension Agreement Follows Successful Two-Year Collaboration in Colon CancerPASADENA, CA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- LI...

 lixte-biotechnology-holdings-announces-the-passing-of-its-founder-and-executive-chairman-john-s-kovach

LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage biotechnology com...

 kirklands-and-2-other-stocks-under-3-insiders-are-buying

The Dow Jones closed lower by around 10 points on Thursday. When insiders purchase or sell shares, it indicates their confidenc...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION